Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.

AIDS (London, England) - 28 Feb 2006

Bani-Sadr Firouzé, Carrat Fabrice, Bedossa Pierre, Piroth Lionel, Cacoub Patrice, Perronne Christian, Degott Claude, Pol Stanislas

Abstract excerpt

OBJECTIVE: To evaluate the prevalence and severity of steatosis and possible interactions between steatosis, host factors, viral factors, and treatment for HIV infection in HIV-hepatitis C virus (HCV) coinfected patients. METHODS: Steatosis was assessed among 395 HIV-HCV coinfected patients who were enrolled in the ANRS trial HC02 Ribavic and for whom histological data were available. Steatosis was graded as...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-HIV Agents
Share to Anti-Retroviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Fatty Liver

Share to Hepatitis C, Chronic

Share to HIV Infections

Share to Liver Cirrhosis

Share to Reverse Transcriptase Inhibitors

Share to Viral Load

Source

Identifiers

PMID: 16470116
DOI: 10.1097/01.aids.0000210606.63138.f5

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.PMID 16470116Read ↗

Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients.Semantic proximity Read ↗

Hepatic steatosis in HIV-HCV coinfected patients in France: comparison with HCV monoinfected patients matched for body mass index and HCV genotype.Semantic proximity Read ↗

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.Semantic proximity Read ↗

HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.Semantic proximity Read ↗

Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.Semantic proximity Read ↗

Hepatic steatosis in chronic hepatitis C: baseline host and viral characteristics and influence on response to therapy with peginterferon alpha-2a plus ribavirin.Semantic proximity Read ↗

Factors associated with liver steatosis and fibrosis in chronic hepatitis C patients.Semantic proximity Read ↗

Human immunodeficiency virus-infected and uninfected adults with non-genotype 3 hepatitis C virus have less hepatic steatosis than adults with neither infection.Semantic proximity Read ↗

Steatosis in chronic hepatitis C: relationship to the virus and host risk factors.Semantic proximity Read ↗

Hepatic steatosis in HIV/HCV co-infected patients: correlates, efficacy and outcomes of anti-HCV therapy: a paired liver biopsy study.Semantic proximity Read ↗

Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors?Semantic proximity Read ↗

Clinical implications of hepatic steatosis in patients with chronic hepatitis C: a multicenter study of U.S. veterans.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.